Increased T-cell stimulating activity by mutated SEC2 correlates with its improved antitumour potency.
To investigate the improved antitumour activity of SAM-3 compared with recombinant staphylococcal enterotoxins C2 (rSEC2). Methylthiazol tetrazolium and flow cytometry assays showed that the antitumour activity of SAM-3 in vivo was improved because of enhanced T-cell stimulating potency, resulting in massive activation of T cells, particularly CD4(+) and CD8(+) T cells, and subsequent cytokine release. Quantitative real-time PCR assay showed that despite similar Vβ specificities induced by rSEC2 and SAM-3, the quantities of activated T cells bearing specific Vβin vitro were different. The results strongly suggested that the increased SAM-3-T-cell receptor (TCR) binding affinity contributed to massive T-cell activation and cytokine release, substantially amplifying antitumour immune response in vivo. This study provided evidence for the mechanism of SAM-3 antitumour activity improvement compared with rSEC2. Results indicated that SAM-3 could be used as a potent powerful candidate agent for tumour treatment in clinics.